Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1993; 70(06): 0915-0920
DOI: 10.1055/s-0038-1649699
DOI: 10.1055/s-0038-1649699
Original Article
Clinical Studies
The Role of β-Fibrinogen Genotype in Determining Plasma Fibrinogen Levels in Young Survivors of Myocardial Infarction and Healthy Controls from Sweden
Authors
Further Information
Publication History
Received 17 March 1993
Accepted after revision 12 July 1993
Publication Date:
06 July 2018 (online)
Summary
β-fibrinogen G/A-455 polymorphism genotype was determined in 123 young survivors of myocardial infarction and 86 healthy controls from Sweden. Frequency of the A-455 allele was 0.25 (95% Confidence Interval 0.21–0.29) in both patients and controls, significantly higher than that reported previously (0.19, 95% Cl 0.16–0.22) in 292 men from the UK (1). Mean plasma fibrinogen level was significantly higher in patients (3.6 g/1) than in controls (3.1 g/1), with p <0.001. Genotype was significantly associated with (adjusted) plasma fibrinogen level in controls (p = 0.003). This effect was confined to the smokers (n = 50) where mean fibrinogen level was significantly (p = 0.001) higher in G/A-455 and A/A-455 individuals (3.5 g/1) compared with G/G-455 homozygotes (2.9 g/1). There was a significant interaction between smoking status and genotype in determining plasma fibrinogen levels in the controls. These data provide independent confirmation of the association between β-fibrinogen G/A-455 genotype and plasma fibrinogen levels previously observed in healthy men from the UK (1).
-
References
- 1 Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemostas 1991; 65: 487-490
- 2 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. New Engl J Med 1984; 311: 501-505
- 3 Stone MC, Thorp JM. Plasma fibrinogen – a major coronary risk factor. J Royal Coll Gen Prac 1985; 35: 565-569
- 4 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease; principal results of the North wick Park Heart Study. Lancet 1986; ii: 533-537
- 5 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease; the Framingham Study. J Amer Med Assoc 1987; 258: 1183-1186
- 6 Balleisen L, Schulte H, Assmann G, Epping P-H, van deLoo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987; ii: 461
- 7 Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990; 85: 169-173
- 8 Lowe GDO, Donnan PT, McColl P. et al. Blood viscosity, fibrinogen and activation of coagulation and leucocytes in peripheral arterial disease: Edinburgh Artery Study. Br J Haematol 1991; 77 (suppl): 27
- 9 Smith WCS, Woodward M, Tunstall-Pedoe H. Intermittent claudication in Scotland. In: Epidemiology of peripheral vascular disease. Fowkes FGR. (ed). London, UK: Springer-Verlag; 1992: 117-123
- 10 Kannel WB, D’Agostino RB. Update of fibrinogen as a major cardiovascular risk factor: the Framingham study. J Am Coll Cardiol 1990; 15: 156A
- 11 Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemostas 1992; 68: 261-263
- 12 Wiseman S, Powell J, Greenhalg R, McCollum C, Kenchington G, Alexander C, Sian M, Franks P. The influence of smoking and plasma factors on prosthetic graft patency. Eur J Vase Surg 1990; 4: 57-61
- 13 Smith EB, Keen GA, Grant A. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-275
- 14 Thompson WD, Smith EB, Stirk CM, Kochhar A. Atherosclerotic plaque growth; presence of stimulatory fibrin degradation products. Blood Coag Fibrinol 1990; 1: 489-493
- 15 Gurewich V, Lipinski B, Hyde F. The effect of the fibrinogen concentration and the leucocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Haemostas 1976; 36: 605-614
- 16 Henschen A, McDonagh J. Fibrinogen, fibrin and factor XIII. In: Blood Coagulation. Zwaal RFA, Hemker HC. (eds). Amsterdam, the Netherlands: Elsevier Science Publishers BV (Biomedical Division); 1986: 171-239
- 17 Meade TW, Vickers MV, Thompson SG, Seghatchian MJ. The effects of physiological levels of fibrinogen on platelet aggregation. Thromb Res 1985; 38: 527-534
- 18 Marguerie G, Ginsberg MH, Plow EF. The role of fibrinogen in platelet aggregation. In: Fibrinogen-Fibrin Formation and Fibrinolysis Vol. 4. Lane DA, Henschen A, Jasani MK. (eds). Berlin, Germany: Walter de Gruyter; 1986: 175-183
- 19 Lowe GDO, Forbes CD. Blood rheology and thrombosis. Clin Lab Haematol 1981; 10: 343-367
- 20 Meade TW, North WRS, Chakrabarti R, Haines AP, Stirling Y. Population-based distributions of haemostatic variables. Br Med Bull 1977; 33: 283-288
- 21 Markowe HLJ, Marmot MG, Shipley MJ. et al. Fibrinogen: a possible link between social class and coronary heart disease. Br Med J 1985; 291: 1312-1314
- 22 Kannel WB, D’Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking and risk of cardiovascular disease: insights from Framingham Study. Am Heart J 1987; 113: 1006-1010
- 23 Rosengren A, Wilhelmsen L, Welin L, Tsipogianni A, Teger-Nilsson AC, Wedel H. Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle-aged men. Br Med J 1990; 300: 634-638
- 24 Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: Scottish Heart Health Study. J Clin Epidemiol 1990; 43: 913-919
- 25 Yarnell JWG, Fehily AM, Milbank J, Rubiki AJ, Eastham R, Hayes TRM. Determinants of plasma lipoproteins and coagulation factors in men from Caerphilly, South Wales. J Epidemiol Commun Health 1983; 37: 137-140
- 26 Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; ii: 986-988
- 27 Abbott RD, Yin Yin, Reed DM, Yano K. Risk of stroke in male cigarette smokers. New Engl J Med 1986; 315: 717-720
- 28 The Health Consequences of Smoking. In: Cardiovascular disease. Report of the Surgeon General. Washington, DC: US Dept Health and Human Services; 1983. p 319
- 29 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205
- 30 Krobot K, Hense HW, Cremer P, Eberle E, Keil U. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age and sex. Arteriosclerosis Thromb 1992; 12: 780-788
- 31 Green GK, Heady A, Oliver MF. Blood pressure, cigarette smoking and heart attack in the WHO co-operative trial of clofibrate. Int J Epidemiol 1989; 18: 355-360
- 32 Meade TW, Brozovic M, Chakrabarti R, Howarth DJ, North WRS, Stirling Y. An epidemiological study of the haemostatic and other effects of oral contraceptives. Br J Haematol 1976; 34: 353-364
- 33 Fuller JH, Keen H, Jarrett RJ. et al. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; ii: 964-966
- 34 Balleisen L, Bailey J, Epping PH, Schulte H, van deLoo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population; I Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using and menopause. Thromb Haemostas 1985; 315: 717-720
- 35 Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979; 1: 153-156
- 36 O’Brien JR, Etherington MD, Jamieson S, Sussex J. The effect of ICI 55,897 and clofibrate on platelet function and other tests abnormal in atherosclerosis. Thromb Haemostas 1978; 40: 75-82
- 37 Pickart L, Thaler MM. Suppression of tumor-associated hyperfibrinogenemia and free fatty acidemia with p-phenoxybenzalbutyrate (clofibrate). Cancer Res 1979; 39: 3845-3848
- 38 Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemostas 1990; 63: 174-177
- 39 Olaisen B, Teisberg P, Gedde-Dahl Jr T. Fibrinogen γ chain locus is on chromosome 4 in man. Hum Genet 1982; 61: 24-26
- 40 Humphries SE, Imam AMA, Robbins TP, Cook M, Carritt B, Ingle C, Williamson R. The identification of a DNA polymorphism of the a fibrinogen gene, and the regional assignment of the human fibrinogen genes to 4q26-qter. Hum Genet 1984; 68: 148-153
- 41 Kant JA, Fornace Jr AJ, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 1985; 82: 2344-2348
- 42 Fey GH, Fuller GM. Regulation of acute phase gene expression by inflammatory mediators. Mol Biol Med 1987; 4: 323-338
- 43 Ritchie DG, Levy BA, Adams MA, Fuller GM. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci USA 1982; 79: 1530-1534
- 44 Birch HE, Schreiber G. Transcriptional regulation of plasma protein synthesis during inflammation. J Biol Chem 1986; 261: 8077-8080
- 45 Fuller GM, Otto JM, Woloski BM, McGary CT, Adams MA. The effects of hepatocyte stimulating factor on fibrinogen biosynthesis in hepatocyte monolayers. J Cell Biol 1985; 101: 1481-1486
- 46 Huber P, Laurent M, Dalmon J. Human β-fibrinogen gene expression. Upstream sequences involved in its tissue specific expression and its dexamethasone and interleukin 6 stimulation. J Biol Chem 1990; 265: 5695-5701
- 47 Hamsten A, de FaireU, Iselius L, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987; ii: 988-991
- 48 Berg K, Kierulf P. DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration. Clin Genet 1989; 36: 229-235
- 49 Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; i: 1452-1455
- 50 Connor JM, Fowkes FGR, Wood J, Smith FB, Donnan PT, Lowe GDO. Genetic variation at fibrinogen loci and plasma fibrinogen levels. J Med Genet 1992; 29: 480-482
- 51 Thompson SG, Martin JC, Meade TW. Sources of variability in coagulation factor assays. Thromb Haemostas 1987; 58: 1073-1077
- 52 Fowkes FGR, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-696
- 53 Hamsten A, Blomback M, Wiman B, Svensson J, Szamosi A, de Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66
- 54 Vermylen C, de VrekerRA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerisation time (FPT). Clin Chim Acta 1963; 8: 418-424
- 55 Laurel CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
- 56 Kunkel LM, Smith KD, Boyer SH, Borgaonkar DS, Wachtel SS, Miller OH, Beg WR, Jones HW, Rary JM. Analysis of human Y-chromosome specific reiterated DNA in chromosome variants. Proc Natl Acad Sci USA 1977; 74: 1245-1249
- 57 Colton T. Inference on Proportions. In: Statistics in Medicine. Boston, USA: Pub: Little, Brown and Company Inc.; 1974. pp 151-188
- 58 Yu S, Sher B, Kudryk B, Redman CM. Intracellular assembly of human fibrinogen. J Biol Chem 1983; 258: 13407-13410
- 59 Roy SN, Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly. Transfection of HepG2 cells with Bβ cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 1990; 265: 6389-6393
- 60 Dalmon J, Laurent M, Courtois G. The human β fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6 responsive element. Mol Cell Biol 1993; 13: 1183-1193